Published in Medical Letter on the CDC and FDA, May 22nd, 2005
The FDA recently concluded the overall risk versus benefit profile for that medication is unfavorable.
In addition, Aetna will inform physicians and members that it is not paying any claims for Bextra prescriptions as of April 7, the day the FDA asked Pfizer, Inc., to withdraw the drug from the market. Aetna Pharmacy Management has instituted computer system edits that will automatically block Bextra prescriptions from being...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.